Jyong Biotech (MENS)
Develops botanical drug candidates for urinary-system diseases.
$2.24
Pre-market0.00 (0.00%)
At close$2.24(−1.32%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions17 holders · as of Mar 31, 2026 | 0.60% | 453.6K shares | |
| Otherremainder | 99.40% | 75.57M shares |
76.03M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F, as of Mar 31, 2026
17 holders · 453.6K shares · 4 new positions · 10 increased · 7 reduced · 6 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 258.8K | 0.34% | −2.1K | May 13, 2026 |
| Geode Capital Management, LLC | 64.2K | 0.08% | −150 | May 15, 2026 |
| UBS Group AG | 37.4K | 0.05% | −108.3K | May 5, 2026 |
| Millennium Management LLC | 14.6K | 0.02% | −25.7K | May 15, 2026 |
| Vanguard Personalized Indexing Management, LLC | 13.9K | 0.02% | +13.9Knew | May 14, 2026 |
| China Universal Asset Management Co., Ltd. | 13.2K | 0.02% | +784 | Apr 28, 2026 |
| HRT Financial LP | 11.8K | 0.02% | +11.8K | May 14, 2026 |
| Tower Research Capital LLC (TRC) | 11.7K | 0.02% | +6.9K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.